Effects of motivational interviewing-based XXXX for @entity161 spectrum disorders: a randomized controlled trial.

@entity1 @entity146 @entity914 @entity161 @entity34
BACKGROUND: Non-adherence to antipsychotic medication is commonly found in @entity161 and other @entity914 , thus forming a major obstacle to long-term maintenance treatment and contributing to high relapse rates. With limited evidence on the success of interventions in enhancing medication adherence, this controlled trial was designed to test and evaluate the effectiveness of an @entity34 ( @entity34 ) for outpatients with @entity161 spectrum disorders, based on a motivational interviewing approach over a six-month follow-up period. METHODS: A single-blind, randomized controlled trial with a repeated-measures, two parallel groups design was conducted in a random sample of 114 @entity1 with @entity161 spectrum disorders in one community @entity146 nursing service. After pre-test, the @entity1 were randomly assigned to either an eight-session course of @entity34 plus usual care or usual @entity146 care (n   =   57 per group). The main outcomes, including medication adherence, symptom severity, insight into treatment, hospitalization rate, and functioning, were measured at baseline and immediately and six months post-intervention. RESULTS: A total of 110 @entity1 completed this trial and thus the attrition rate was 3.5  %. Results of repeated-measures analysis of variance followed by Helmert's contrasts test indicated that the @entity34 @entity1 reported significantly greater improvements in their insight into illness and/or treatment, psychosocial functioning, symptom severity, number of re-hospitalizations, and medication adherence (F   =   5.01 to 7.45, P   =   0.007 to 0.030) over six months follow-up, when compared with usual care. CONCLUSIONS: Motivational interviewing-based @entity34 for @entity1 with @entity161 can be effective to reduce symptom severity and re-hospitalizations, and improve medication adherence, functioning, and insight into illness and/or treatment over a medium term (six months) period of follow-up. Further study on the effects of @entity34 in @entity1 with @entity914 in terms of diverse sociodemographic and illness characteristics, and a longer term (for example, over 12  months) follow-up period is recommended. TRIAL REGISTRATION: The trial was registered at Clinicaltrials.gov (identifier: NCT01780116 ) on 6 July 2014.
